PEM-related references (June 23, 2014)

[1] Siegel R, Naishadham D, and Siegel A J: Cancer statistics. CA: A Cancer Journal for Clinicians 62(1):10-29, 2012; PMID: 22237781.

[2] National Cancer Institute (NCI) on the Internet: Breast Cancer, NCI at National Institute of Health, http://www.cancer.gov/cancertopics/types/breast, 2012.

[3] Oshida M, Uno K, Suzuki M, et al.: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 82(11):2227-2234, 2000; PMID: 9610703.

[4] Mankoff DA, Dunnwald LK, Gralow JR, et al.: “Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43:500-509, 2002; PMID: 11937594.

[5] Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101-2111, 1993; PMID: 8229124.

[6] Mankoff DA, Dunnwald LK: Changes in glucose metabolism and blood flow following chemotherapy for breast cancer. PET Clin 1:71-81, 2006; PMID: 14602864.

[7] Smith IC, Welch AE, Hutcheon AW, et al.: Positron emission tomography using [(18)F]-fluorodeoxy-Dglucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18(8):1676-1688, 2000; PMID: 10764428.

[8] Schelling M, Avril N, Nahrig J, et al.: Positron emission tomography using [18F] fluorodeoxy-glucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18(8):1689-1695, 2000; PMID: 10764429.

[9] Linden HM, Stekhova SA, Link JM, et al.: Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment. J Clin Oncol 24(18):2793-99, 2006; PMID: 16682724.

[10] Dehdashti F, Mortimer JE, Trinkaus K, et al.: PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer, Breast Cancer Res Treat 113:509-517, 2009; PMID: 18327670.

[11] Mayer IA, Abramson VG, Isakoff SJ, et al.: Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide- 3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer, J Clin Onc, e-pub ahead of print, Mar. 2014; PMID: 24663045.

[12] Gebhart G, Gamez C, Holmes E, et al.: 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 54(11):1862–1868, Nov. 2013; PMID: 24092940.

[13] Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M, Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations, J.Clin.Oncol., 18(20):3495-3502, 2000; PMID: 11032590.

[14] Weber W: Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46(6):983- 995, 2005; PMID: 15937310.

[15] Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.

[16] Wang GC, Huber JS, Moses WW, Qi J, Choong WS: Characterization of the LBNL PEM Camera. IEEE

Trans Nucl Sci 53(3):1129-1135, 2006.

[17] Thompson CJ, Murthy K, Weinberg IN, Mako F: Feasibility of positron emission mammography. Med Phys 21:529-538, 1994; PMID: 8058019.

[18] Thompson CJ, Murthy K, Picard Y, Weinberg IN: Positron emission mammography (PEM): a promising technique for detecting breast cancer. IEEE Trans Nucl Sci 42(4):1012-1017, 1995.

[19] Weinberg IN, Majewski S, Wojcik R, Weisenberger AG, et al.: Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammographic gantry. Eur J Nucl Med 23:804-806, 1996; PMID: 8662120.

[20] Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH: Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 41:1851-1858, 2000; PMID: 11079494.

[21] Doshi NK, Shao Y, Silverman RW, Cherry SR: Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 27(7):1535-1543, 2000; PMID: 10947256.

[22] Raylman RR, Majewski S, Wojcik R, Weisenberger AG, Kross B, Popov V, Bishop HA: The potential role of positron emission mammography for detection of breast cancer. A phantom study. Med Phys 27(8):1943-1954, 2000; PMID: 10984240.

[23] Murthy K, Aznar M, Bergman AM, et al.: Positron emission mammographic instrument: initial results. Radiology 215:280-285, 2000; PMID: 10751499.

[24] Adler LP, Weinberg IN, Bradbury MS, et al.: Method for combined FDG-PET and radiographic imaging of primary breast cancers. Breast 9:163-166, 2003; PMID: 12752623.

[25] Levine EA, Freimanis RI, Perrier ND, et al.: Positron emission mammography: initial clinical results. Ann Surg Oncol 10:86-91, 2003; PMID: 12513966.

[26] Turkington TG, Majewski S, Weisenberger AG, et al.: A large field of view positron emission mammography imager. IEEE NSS-MIC Conf Rec 3, pgs:1883 – 1886, 2002.

[27] Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE: Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 234:527-534, 2005; PMID: 15671006.

[28] Tafra L, Cheng Z, Uddo J, et. al: Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 190:628-632, 2005; PMID: 16164937.

[29] Abreu MC, Aguiar D, Albuquerque E, et. al: Clear-PEM: A PET imaging system dedicated to breast cancer research. Nucl Instr Meth A 571:81-84, 2007; PMID: 16604628

[30] Raylman R, Majewski S, and Smith M, et. al: The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol 53(3):637-653, 2008; PMID: 18199907.

[31] Bowen SL, Wu Y, and Chaudhari AJ, et. al: Initial characterization of a dedicated breast PET/CT scanner during human imaging. J. Nucl Med 50:1401-08, 2009; PMID: 19690029.

[32] LR MacDonald, J Edwards, T Lewellen, et al., Clinical imaging characteristics of the positron emission mammography camera: PET Flex Solo II. J. Nucl. Med 50:1666-1675, 2009; PMID: 19759118.

[33] Ravindranath B, Junnarkar SS, Purschke ML, et al., Results from prototype II of the BNL simultaneous PET-MRI dedicated breast scanner, IEEE NSS-MIC Conf Rec 2009:3315 – 3317, 2009.

[34] Linden HM and Dehdashti F: Novel Methods and Tracers for Breast Cancer Imaging, Semin Nucl Med 43:324-329, 2013; PMID: 23725994.

[35] Springer M: Evaluation of the quantitative accuracy of a commercially-available positron emission mammography scanner, Med Phys 38(4):2132-39, 2011; PMID: 21626946.

[36] Furuta M, Kitamura K, Ohi J, et. al: Basic evaluation of a C-shaped breast PET scanner. IEEE NSS-MIC Conf Rec 2009:2548–2552, 2009.

[37] Peng H and Levin C: Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectors. Phys Med Biol 55:2761–2788, 2010; PMID: 20400807.

[38] Koolen BB, Aukema TS, González-Martínez AJ, et al.: First clinical experience with a dedicated PET for hanging breast molecular imaging. Q J Nucl Med Mol Imag 57(1):92–100, Mar. 2013; PMID: 23474637.

[39] Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y, Toi M, and Togashi K: Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation. J Nucl Med 53(10):1534– 1542, Oct. 2012; PMID: 22933819.

[40] Brasse D, Kinahan PE, Clackdoyle R, Defrise M, Comtat C, and Townsend DW: Fast fully 3-D image reconstruction in PET using planograms. IEEE Trans Med Imag 23(4):413–425, Apr. 2004; PMID: 15084067.

[41] Tong S, Alessio A, and Kinahan P: Image reconstruction for PET/CT scanners: past achievements and future challenges. Imaging in Med 2(5):529–545, 2010; PMID: 21339831.

[42] Tong S, Alessio A, Thielemans K, Stearns C, Ross S, and Kinahan P: Properties and Mitigation of Edge Artifacts in PSF-Based PET Reconstruction. IEEE Trans Nucl Sci 58(5):2264–2275, 2011.

[43] Tong S, Alessio AM, Kinahan PE: Noise and signal properties in PSF-based fully 3D PET image reconstruction: an experimental evaluation. Phys Med Biol 55(5):1453–1473, 2010; PMID: 20150683.

[44] Champley K, Defrise M, Clackdoyle R, Raylman RR, and Kinahan PE: Planogram rebinning with the frequency-distance relationship. IEEE Trans Med Imag 27(7):925–933, Jan. 2008; PMID: 18599398.

[45] Champley KM, Raylman RR, and Kinahan PE: Advancements to the planogram frequency-distance rebinning algorithm. Inverse Probl, 26(4):045008, 2010; PMCID: PMC2861831.

[46] Long Y, Fessler JA, and Balter JM: 3D forward and back-projection for X-ray CT using separable footprints. IEEE Trans Med Imag 29(11):1839–1850, Nov. 2010; PMID: 20529732.

[47] Kinahan PE, Zeng G, Pierce II LA, Kanal KM, MacDonald LR: Attenuation Correction Using a Single-View Mammogram for a 3D PET Scanner. Proc Fully 3D Image Recon in Rad and Nucl Med. 2013:261–263. Granlibakken Resort, Lake Tahoe, CA, June 16-21, 2013.

[48] Nuyts J, Bal G, Kehren F, Fenchel M, Michel C, and Watson C: Completion of a truncated attenuation image from the attenuated PET emission data. IEEE Trans Med Imag 32(2):237–246, Feb. 2013; PMID: 23014717.

[49] MacDonald LR, Hunter WCJ, Kinahan PE, Miyaoka RS, Effects of Detector Thickness on Geometric Sensitivity and Event Positioning Errors in the Rectangular PET/X Scanner. IEEE Trans Nucl Sci 60(5):3242–3252, 2013.

[50] Harrison RL, Vannoy SD, Haynor DR, Gillispie SB, Kaplan MS, and Lewellen TK: Preliminary Experience With The Photon History Generator Module Of A Public-domain Simulation System For Emission Tomography. Nucl Sci Symp and Med Imag Conf Rec 1993:1154–1158, San Francisco, CA, 31Oct–6Nov, 1993.

[51] Man BD and Basu S: Distance-driven projection and backprojection in three dimensions. Phys Med Biol 49(11):2463–2475, May 2004; PMID: 15248590.

[52] Pierce II LA, Champley KM, Kinahan PE, and MacDonald LR: Tube of Response Sensitivity Variations in a Full FOV Rectangular PET System. IEEE Med Imag Conf Rec, 2013 (not yet released), Seoul, Korea, October 2013.

[53] Fessler JA and Booth SD: Conjugate-gradient preconditioning methods for shift-variant PET image reconstruction. IEEE Trans. Imag Process 8(5):688–699 1999; PMID: 18267484.

[54] Fessler JA: Penalized Weighted Least-Squares Image Reconstruction for Positron Emission Tomography. IEEE Trans Med Imag 13:290–300, 1994; PMID: 18218505.

[55] Qi J and Leahy RM: Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans Med Imag 19(5):493–506, May 2000; PMID: 11021692.

[56] Nuyts J, Dupont P, Stroobants S, Benninck R, Mortelmans L, and Suetens P: Simultaneous maximum a posteriori reconstruction of attenuation and activity distributions from emission sonograms. IEEE Trans Med Imag 18(5):393–403, May 1999; PMID: 10416801.

[57] Bergström M, Eriksson L, Bohm C, Blomqvist G, and Litton J: Correction for Scattered Radiation in a Ring Detector Positron Camera by Integral Transformation of the Projections. J Comput Assist Tomogr 7(1):42–50, 1983; PMID: 6600755.

[58] Smith RJ and Karp JS: A practical method for randoms subtraction in volume imaging PET from detector singles countrate measurements. IEEE Trans Nucl Sci 43(3):1981–1987, 1996.

[59] Brasse D, Kinahan PE, Lartizien C, Comtat C, Casey M, and Michel C: Correction methods for random coincidences in fully 3D whole-body PET: Impact on data and image quality. J Nucl Med 46(5):859–867, May 2005; PMID: 15872361.

[60] Defrise M, Townsend DW, Bailey D, Geissbuhler A, Michel C, and Jones T: A normalization technique for 3D PET data. Phys Med Biol 36(7):939–952, Jul. 1991; PMID: 1886928.

[61] Bai B, Li Q, Holdsworth CH, Asma E, Tai YC, Chatziioannou A, and Leahy RM: Model-based normalization for iterative 3D PET image reconstruction. Phys Med Biol 47(15):2773–2784, Aug. 2002; PMID: 12200938.

[62] Meyer CR, Armato SG, Fenimore CP, et al.: Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources. Transl Oncol 2(4):198–210, 2009. PMID: 19956379.

[63] Lee K, Miyaoka RS, Lewellen TK, Alessio AM, Kinahan PE: Impact on Image Noise of Incorporating Detector Blurring into Image Reconstruction for a Small Animal PET Scanner. IEEE Trans Nucl Sci 56(5):2769–2776, 2009. PMID: 20161545.

[64] Lee K, Kinahan PE, Miyaoka RS, Kim JS, Lewellen TK: Impact of system design parameters on image figures of merit for a mouse PET scanner. IEEE Trans Nucl Sci 51(1):27–33, 2004.

[65] Barrett HH, Myers K: Foundations of Image Science. Ed. Saleh BEA, Hoboken, New Jersey, Wiley & Sons: 2004.

[66] Fawcett T: An introduction to ROC analysis. Pattern recognition letters 27(8):861–874, 2006.

[67] Kinahan PE, Townsend DW, Beyer T, and Sashin D: Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25(10):2046-2053, 1998; PMID: 9800714.

[68] Grootoonk  S, Spinks TJ, Sashin D, Spyrou NM, and Jones T:  Correction  for scatter  in 3D brain PET using a dual energy window method.   Phys Med Biol  41(12):2757–2774, 1996; PMID: 8971967.

[69] Watson CC, Casey ME, Christian M, and Bendriem B: Advances in Scatter Correction for 3D PET/CT IEEE Nucl Sci Symp and Med Imag Conf Rec 2004:1–5, Oct. 2004.

 

Additional References (may be duplicates from above list)

1. Anderson BO, Braun S, Carlson RW, Gralow JR, Lagios MD, Lehman CD, Schwartsmann G, Vargas H. Global Summit Consensus Conference on International Breast Health Care: Overview of Breast Health Care Guidelines for Countries with Limited Resources. Breast J. 2003 May-Jun;9 Suppl 2:S42-50.

2. Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Kobrunner SH, Hylton N, Kuhl CK, Lehman CD, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall MD. Magnetic Resonance Imaging of the Breast Prior to Biopsy. JAMA. 2004 Dec 8;292(22):2735-42.

3. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O’Loughlin M, Harms S, Bluemke DA, International Breast MRI Consortium Working Group. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005 May 1;103:1898-905. (PMID: 15800894)

4. Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB Lehman CD, Weatherall PT, Gatsonis CA. MRI Detection of Distinct Incidental Cancer in Women with Primary Breast Cancer Studied in IBMC 6883. J Surg Oncol. 2005 Oct 1;92(1):32-8.

5. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, Carney PA, Kerlikowske K, Buist DSM, Weaver DL, Barlow WE, Ballard-Barbash R. Performance Benchmarks for Screening Mammography. Radiology. 2006 Oct;241 55-66. (PMID: 16990671)

6. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD; ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007 Mar 29;356(13):1295-303. (PMID: 17392300)

7. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. (PMID: 17392385)

8. Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ,Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C. Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study. Radiology. 2007 Aug;244(2):381-388. (PMID: 17641362)

9. Gallagher TH, Cook AJ, Brenner RJ, Carney PA, Miglioretti DL, Geller B, Kerlikowske K, Onega T, Rosenberg RD, Yankaskas B, Lehman CD, Elmore JG. Disclosing Harmful Mammography Errors to Patients. Radiology. 2009 Nov;253(2):443-52. (PMID: 19710002) (PMC2770115).

10. Lehman CD, Smith RA. The Role of MRI in Breast Cancer Screening. J Natl Compr Canc Netw. 2009 Nov;7(10):1109-15.(PMID: 19930977).

11. Lehman CD. Magnetic Resonance Imaging in the Evaluation of Ductal Carcinoma In Situ. J Natl Cancer Inst. Monogr. 2010;2010(41):150-151. (PMID:20956821).

12. DeMartini WB, Kurland BF, Gutierrez RL, Blackmore CC, Peacock S, Lehman CD. Probability of Malignancy for Lesions Detected on Breast MRI: A Predictive Model Incorporating BI-RADS Imaging Features and Patient Characteristics. European Radiology {Epub 2011 Feb 27 ] Eur Radiol. 2011 Aug;21(8):1609-17. (PMID:21359910).

13. Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD, Taplin SH, Sickles EA; for the Breast Cancer Surveillance Consortium. Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States: A Cohort Study. Ann Intern Med. 2011 Oct 18;155(8):493-502. (PMID: 22007043) (PMC3726800).

14. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton MB, Hudis C, Gray J, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JS, Dressler L, Chhieng D, Singh S, Mies C, Rabban, J, ChenY, Giri D, van ‘t Veer L, I-SPY 1 TRIAL Investigators, Hylton N. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Journal of Clinical Oncology. 2012 May [Epub ahead of print] (PMID:22649152) (PMC3434983).

15. Huynh PT, Lemeshko SV, Mahoney MC, Newell MS, Bailey L, Barke LD, D’Orsi C, Harvey JA, Hayes MK,Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG. ACR Appropriateness Criteria® Stage I Breast Carcinoma. J Am Coll Radiol. 2012 Jul;9(7):463-7 (PMID: 22748785).

16. Lehman CD, Lee CI, Loving V, Portillo MS, Peacock S, DeMartini WB. Accuracy and Value of Breast Ultrasound for Primary Imaging Evaluation of Symptomatic Women 30 to 39 Years of Age. AJR 2012 Nov;199(5):1169-77 (PMID:23096195)

17. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD for the ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators. Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy – Results from ACRIN 6657/I-SPY Trial. Radiology 2012 June; 263:663-672 (PMID: 22623692) (PMC3359517).

18. Lee CI, Bassett L, Lehman CD. Breast Density Legislation and Opportunities for Patient-Centered Outcomes Research. Radiology 2012 Sep;264,632-6.

19. Harvey JA, Mahoney MC, Newell MS, Bailey L, Barke LD, D’Orsi C, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, Handel RE, Sutherland L, Haffty BG. ACR Appropriateness Criteria® Palpable Breast Masses. J Am coll Radiol 2013;10:742-749 (PMID:24091044).

20. Lee CI, Bensink ME, Berry K, Musa Z, Bodnar C, Dann R, Jarvik JG, Lehman CD, Ramsey SD. Performance goals for an adjust diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits, and consequences. J Am Coll Radiol 2013; 10(11):924-930 (PMID: 2429542).